Lu Yun
The First College of Clinical Medical Science, China Three Gorges University and Yichang Central People's Hospital, Yichang, Hubei, China.
Pak J Pharm Sci. 2026 Jan;39(1):249-260. doi: 10.36721/PJPS.2026.39.1.REG.13817.1.
Chronic insomnia impairs health-related quality of life and current pharmacotherapies carry substantial adverse-effect profiles, prompting the search for safer multi-target interventions. Kong Sheng Pillow Zhongdan (KSPZ), a classical herbal formula, is empirically used for sleep disturbance, yet its molecular basis remains unclear.
To elucidate the putative mechanisms of KSPZ against chronic insomnia through a network-pharmacology approach and to prioritise targets for experimental validation.
Active compounds were retrieved from TCMSP, HIT2.0 and TCMIP and filtered by oral bioavailability ≥30% and blood-brain barrier permeability ≥-0.3. Insomnia-related genes were collected from DisGeNET, GeneCards and OMIM. Overlapping targets defined the "core prescription-insomnia" interactome (126 genes). Protein-protein interaction networks were constructed with STRING and hub nodes identified by CytoHubba. GO, KEGG and Reactome enrichment analyses were performed with clusterProfiler; key ligand-target pairs were evaluated by AutoDock Vina. A drug-ingredient-target-disease network was visualised in Cytoscape.
Twenty-eight bioactive compounds (e.g., quercetin, kaempferol, luteolin) were mapped to 126 shared targets enriched in neuro-inflammation (IL-17, TNF, NF-κB), serotonergic and dopaminergic synapses, circadian rhythm and cAMP signalling. Top hub genes included TNF, IL6, AKT1, PTGS2, BDNF and DRD2. Molecular docking showed high affinities (ΔG ≤ -8.5 kcal mol) for quercetin-GABRA1, kaempferol-HTR2A and luteolin-BDNF complexes, supporting modulatory effects on inhibitory/excitatory neurotransmission and neuroplasticity.
KSPZ exerts multi-level effects on neuro-immune regulation, inflammation and circadian pathways, providing a rational basis for its empirical use in chronic insomnia. In-vivo validation of the predicted neurotransmitter and cytokine targets is warranted to translate these network findings into clinical applications.
慢性失眠会损害与健康相关的生活质量,目前的药物治疗具有大量不良反应,促使人们寻找更安全的多靶点干预措施。孔圣枕中丹(KSPZ)是一种经典的中药配方,经验证可用于治疗睡眠障碍,但其分子机制尚不清楚。
通过网络药理学方法阐明KSPZ治疗慢性失眠的潜在机制,并确定实验验证的优先靶点。
从中药系统药理学数据库与分析平台(TCMSP)、HIT2.0和中医整合药理学平台(TCMIP)中检索活性成分,并通过口服生物利用度≥30%和血脑屏障通透性≥ -0.3进行筛选。从疾病基因数据库(DisGeNET)、基因卡片(GeneCards)和在线人类孟德尔遗传数据库(OMIM)中收集失眠相关基因。重叠靶点定义了“核心方剂 - 失眠”相互作用组(126个基因)。使用STRING构建蛋白质 - 蛋白质相互作用网络,并通过CytoHubba识别枢纽节点。使用clusterProfiler进行基因本体(GO)、京都基因与基因组百科全书(KEGG)和Reactome富集分析;通过AutoDock Vina评估关键配体 - 靶点对。在Cytoscape中可视化药物 - 成分 - 靶点 - 疾病网络。
28种生物活性化合物(如槲皮素、山奈酚、木犀草素)被映射到126个共同靶点,这些靶点富集于神经炎症(白细胞介素 - 17、肿瘤坏死因子、核因子 - κB)、血清素能和多巴胺能突触、昼夜节律和环磷酸腺苷(cAMP)信号传导。顶级枢纽基因包括肿瘤坏死因子、白细胞介素6、蛋白激酶B1、前列腺素内过氧化物合酶2、脑源性神经营养因子和多巴胺受体D2。分子对接显示槲皮素 - γ - 氨基丁酸A型受体1(GABRA1)、山奈酚 - 5 - 羟色胺受体2A(HTR2A)和木犀草素 - 脑源性神经营养因子(BDNF)复合物具有高亲和力(结合自由能ΔG≤ -8.5千卡/摩尔),支持其对抑制性/兴奋性神经传递和神经可塑性的调节作用。
KSPZ对神经免疫调节、炎症和昼夜节律途径具有多层次作用,为其在慢性失眠中的经验性应用提供了合理依据。有必要对预测的神经递质和细胞因子靶点进行体内验证,以便将这些网络研究结果转化为临床应用。